{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:04:38Z","timestamp":1649045078982},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10620-019-05534-5","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T09:54:41Z","timestamp":1550483681000},"page":"685-688","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin"],"prefix":"10.1007","volume":"64","author":[{"given":"Muhammad B.","family":"Hammami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Thiruvengadam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendall","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Kattah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"5534_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"20","author":"SH Baumeister","year":"2016","unstructured":"Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;20:539\u2013573.","journal-title":"Annu Rev Immunol"},{"key":"5534_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","volume":"19","author":"CA Chambers","year":"2001","unstructured":"Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565\u2013594.","journal-title":"Annu Rev Immunol"},{"key":"5534_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"5534_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98\u2013106.","journal-title":"Am J Clin Oncol"},{"key":"5534_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"25","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;25:1\u201310.","journal-title":"Immunity"},{"key":"5534_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"11","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;11:122\u2013133.","journal-title":"N Engl J Med"},{"key":"5534_CR7","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"21","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;21:2006\u20132017.","journal-title":"N Engl J Med"},{"key":"5534_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"2","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;2:23\u201334.","journal-title":"N Engl J Med"},{"key":"5534_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/PPO.0000000000000186","volume":"22","author":"R Dadu","year":"2016","unstructured":"Dadu R, Zobniw C, Diab A. Managing adverse events with immune checkpoint agents. Cancer J. 2016;22:121\u2013129.","journal-title":"Cancer J"},{"key":"5534_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u2013148.","journal-title":"Eur J Cancer"},{"key":"5534_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"11","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;11:158\u2013168.","journal-title":"N Engl J Med"},{"key":"5534_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11523-017-0495-4","volume":"12","author":"C Prieux-Klotz","year":"2017","unstructured":"Prieux-Klotz C, Dior M, Damotte D, et al. Immune checkpoint inhibitor-induced colitis: diagnosis and management. Target Oncol. 2017;12:301\u2013308.","journal-title":"Target Oncol"},{"key":"5534_CR13","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"10","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;10:1714\u20131768.","journal-title":"J Clin Oncol"},{"key":"5534_CR14","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"25","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;25:2521\u20132532.","journal-title":"N Engl J Med"},{"key":"5534_CR15","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"10","author":"S Zelenay","year":"2015","unstructured":"Zelenay S, van der Veen AG, B\u00f6ttcher JP, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;10:1257\u20131270.","journal-title":"Cell"},{"key":"5534_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmed.2015.11.003","volume":"22","author":"D Wang","year":"2016","unstructured":"Wang D, DuBois RN. The role of prostaglandin E(2) in tumor-associated immunosuppression. Trends Mol Med. 2016;22:1\u20133.","journal-title":"Trends Mol Med"},{"key":"5534_CR17","doi-asserted-by":"publisher","first-page":"A79","DOI":"10.1136\/gutjnl-2015-311237","volume":"67","author":"H Ibraheim","year":"2018","unstructured":"Ibraheim H, Samaan M, Powell N. P480 effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced diarrhoea\/colitis. Gut. 2018;67:A79.","journal-title":"Gut"},{"key":"5534_CR18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","volume":"66","author":"V Bergqvist","year":"2017","unstructured":"Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581\u2013592.","journal-title":"Cancer Immunol Immunother"},{"key":"5534_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","volume":"71","author":"DM Karamchandani","year":"2018","unstructured":"Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists\u2019 perspective. J Clin Pathol. 2018;71:665\u2013671.","journal-title":"J Clin Pathol"},{"key":"5534_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1128\/CMR.00039-09","volume":"23","author":"JM Janda","year":"2010","unstructured":"Janda JM, Abbott SL. The genus Aeromonas: taxonomy, pathogenicity, and infection. Clin Microbiol Rev. 2010;23:35\u201373.","journal-title":"Clin Microbiol Rev"},{"key":"5534_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/gut.30.5.686","volume":"30","author":"JM Willoughby","year":"1989","unstructured":"Willoughby JM, Rahman AF, Gregory MM. Chronic colitis after Aeromonas infection. Gut. 1989;30:686\u2013690.","journal-title":"Gut"},{"key":"5534_CR22","first-page":"71","volume":"21","author":"T Lobat\u00f3n","year":"2015","unstructured":"Lobat\u00f3n T, Hoffman I, Vermeire S, Ferrante M, Verhaegen J, Van Assche G. Aeromonas species: an opportunistic enteropathogen in patients with inflammatory bowel diseases? A single center cohort study. GUT. 2015;21:71\u201378.","journal-title":"GUT"},{"key":"5534_CR23","doi-asserted-by":"publisher","first-page":"e0189377","DOI":"10.1371\/journal.pone.0189377","volume":"12","author":"W-C Lin","year":"2017","unstructured":"Lin W-C, Chang C-W, Chen M-J, et al. Challenges in the diagnosis of ulcerative colitis with concomitant bacterial infections and chronic infectious colitis. PLoS ONE. 2017;12:e0189377.","journal-title":"PLoS ONE"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-05534-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T11:00:07Z","timestamp":1582023607000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-05534-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["5534"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-05534-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"18 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}